Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Christelle Clément Duchene"'
Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC
Autor:
Calcagno Fabien, Eric Dansin, Virginie Westeel, Pascal Thomas, Jose Carlos Benitez, Jean-Michel Maury, Pierre-Emmanuel Falcoz, Laurence Bigay-Game, F. Thillays, Christelle Clément Duchene, Lyubimova Svetlana, Thierry Molina, Marie Eve Boucher, Benjamin Besse, Eric Pichon, P. Missy, Nicolas Girard, Luc Thiberville, Youssef Oulkhouir, Mallorie Kerjouan
Publikováno v:
Journal of Clinical Oncology. 39:8578-8578
8578 Background: TETs are rare and potentially aggressive malignancies with high associated prevalence of autoimmune disorders (AIDs). The pleura is the main metastatic site at relapse, referred as Masaoka-Koga stage (MK) IVa. The benefit of surgical
Autor:
Marylise Ginoux, Luc Thiberville, Youssef Oulkhouir, Nicolas Girard, Mallorie Kerjouan, Thierry Molina, Xavier Quantin, Bertrand Mennecier, Eric Pichon, Laurence Bigay-Game, Christelle Clément Duchene, Calcagno Fabien, F. Thillays, Laurent Greillier, Benjamin Besse, Arthur Petat, Charles Ricordel, Pierre Fournel, Eric Dansin, Virginie Westeel
Publikováno v:
Journal of Clinical Oncology. 38:9072-9072
9072 Background: Thymic carcinomas are an aggressive and difficult to treat subset of thymic epithelial tumors (TETs) that represent a heterogeneous group of rare intrathoracic malignancies. Most of the current knowledge and guidelines tumors rely on
Autor:
Nicolas Girard, Jose Carlos Benitez, Benjamin Besse, Thierry Jo Molina, Calcagno Fabien, P. Missy, F. Thillays, Julien Mazieres, Eric Dansin, Marie Eve Boucher, Eric Pichon, Franck Morin, Jean-Michel Maury, Benoit Roch, Luc Thiberville, Pierre-Emmanuel Falcoz, Youssef Oulkhouir, Mallorie Kerjouan, Christelle Clément Duchene, Pascal Thomas
Publikováno v:
Journal of Clinical Oncology. 38:9073-9073
9073 Background: TET are associated with autoimmune disorders (AID) in up to 30% of patients (pts). However, there have been wide variations in the reported prevalence of AID in TET pts in small single-center series. RYTHMIC (Réseau tumeurs THYMique
Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Autor:
Pierre Saintingy, Solène Marteau, Anne Pradines, Karen Howarth, Emma Green, Aurélie Swalduz, Gilles Clapisson, Jean-Yves Blay, Etienne Brain, Etienne Giroux Leprieur, Frank de Kievit, C. Raynaud, Virginie Avrillon, Virginie Westeel, Isabelle Monnet, Xavier Quantin, Nathalie Hoog-Labouret, Julien Mazieres, Claire Tissot, Séverine Martinez, Radj Gervais, Clive Morris, Celine Mahier, Y. Loriot, Washington René Chumbi Flores, Sandra Ortiz-Cuaran, Séverine Neymarc, Nathalie Girerd-Chambaz, Maurice Pérol, Christelle Clément Duchene
Publikováno v:
Cancer Research. 78:1841-1841
Background: BRAF mutations occur in 2 to 3% of patients (pts) with non-small cell lung cancer (NSCLC). In these pts vemurafenib, a selective oral BRAF inhibitor is associated with a response rate (RR) of 42%, rising to 64% for combination treatment w